Response of Topical Capsaicin in Alopecia Areata
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
It has been postulated that Alopecia Areata (AA) is, at least in part, a neurologically mediated disease. Research supporting this theory includes the finding that nerves surrounding the hair follicles are collapsed. We want to take this research a step further and show that not only are these perifollicular nerves collapsed, but that their function is also impaired.
| Condition | Intervention | Phase |
|---|---|---|
|
Alopecia Areata |
Drug: Capsaicin |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin |
- Topical capsaicin will quantitatively decrease the amount of Substance P in the scalp of AA patients.
- The scalps of AA patients may be less sensitive to stimuli.
| Estimated Enrollment: | 24 |
| Study Start Date: | August 1997 |
| Estimated Study Completion Date: | June 2000 |
To assess the function of perifollicular scalp nerves in AA we will look at the response of these nerves to the topical medication capsaicin. Under normal circumstances topical capsaicin is known to target nerves in the peripheral nervous system causing short-term release of the neuropeptide Substance P (SP) as well as long-term transient depletion of SP. We expect the AA patients will respond abnormally to topical capsaicin treatment.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Must have alopecia totalis or universalis.
- Be in good health.
- Not be taking any medications including topical medications
- Be 18 years or older.
- Be willing to apply study medication or vehicle as directed, comply with instructions and commit to follow-up visits.
- Not have had hair chemically treated (including colored hair, permed hair, etc) within the month prior to the study.
Exclusion Criteria:
- Absence of extensive alopecia areata.
- People not in good health.
- People taking medications.
- Allergies to capsaicin.
- Presence of irritated or visibly inflamed scalp.
- Having had hair chemically treated (including colored hair, permed hair, etc.) within the month prior to study.
Contacts and Locations| United States, Minnesota | |
| University of Minnesota | |
| Minneapolis, Minnesota, United States, 55455 | |
| Principal Investigator: | Maria Hordinsky, MD | University of Minnesota - Clinical and Translational Science Institute |
| Principal Investigator: | Marna Ericson, Ph D | University of Minnesota - Clinical and Translational Science Institute |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00176969 History of Changes |
| Other Study ID Numbers: | 9707M00122 |
| Study First Received: | September 12, 2005 |
| Last Updated: | November 8, 2006 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical Capsaicin |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Antipruritics Dermatologic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013